These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34976467)

  • 21. Psoriasis and metabolic syndrome.
    Sales R; Torres T
    Acta Dermatovenerol Croat; 2014; 22(3):169-74. PubMed ID: 25230056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolic syndrome. Preliminary report.
    Brito-Luna MJ; Villanueva-Quintero DG; Sandoval-Talamantes AK; Fafutis-Morris M; Graciano-Machuca O; Sanchez-Hernandez PE; Alvarado-Navarro A
    Cytokine; 2016 Sep; 85():130-6. PubMed ID: 27344023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psoriasis: the visible killer.
    Torres T; Bettencourt N
    Rev Port Cardiol; 2014 Feb; 33(2):95-9. PubMed ID: 24525359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psoriasis and cardiovascular comorbidities with emphasis in Asia.
    Chu TW; Tsai TF
    G Ital Dermatol Venereol; 2012 Apr; 147(2):189-202. PubMed ID: 22481582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.
    Caiazzo G; Fabbrocini G; Di Caprio R; Raimondo A; Scala E; Balato N; Balato A
    Front Immunol; 2018; 9():1668. PubMed ID: 30150978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges.
    Pannu S; Rosmarin D
    Am J Clin Dermatol; 2021 May; 22(3):293-300. PubMed ID: 33586126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease.
    Bonanad C; González-Parra E; Rivera R; Carrascosa JM; Daudén E; Olveira A; Botella-Estrada R
    Actas Dermosifiliogr; 2017 Nov; 108(9):800-808. PubMed ID: 28610662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities.
    Krueger JG; Brunner PM
    Exp Dermatol; 2018 Feb; 27(2):115-123. PubMed ID: 29152791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comorbidities and psoriasis. Impact on clinical practice].
    Gerdes S; Mrowietz U
    Hautarzt; 2012 Mar; 63(3):202-13. PubMed ID: 22373901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications.
    von Stebut E; Boehncke WH; Ghoreschi K; Gori T; Kaya Z; Thaci D; Schäffler A
    Front Immunol; 2019; 10():3096. PubMed ID: 32010143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities.
    Gisondi P; Bellinato F; Girolomoni G; Albanesi C
    Front Pharmacol; 2020; 11():117. PubMed ID: 32161545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association of psoriasis and hypertension: focusing on anti-inflammatory therapies and immunological mechanisms.
    Hu MY; Yang Q; Zheng J
    Clin Exp Dermatol; 2020 Oct; 45(7):836-840. PubMed ID: 32789979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
    Ahlehoff O; Skov L; Gislason G; Gniadecki R; Iversen L; Bryld LE; Lasthein S; Lindhardsen J; Kristensen SL; Torp-Pedersen C; Hansen PR
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1128-34. PubMed ID: 25303139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?
    Orlando G; Molon B; Viola A; Alaibac M; Angioni R; Piaserico S
    Front Immunol; 2022; 13():868277. PubMed ID: 35686132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologics for Reducing Cardiovascular Risk in Psoriasis Patients.
    Terui H; Asano Y
    J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response.
    Chen Z; Hu Y; Gong Y; Zhang X; Cui L; Chen R; Yu Y; Yu Q; Chen Y; Diao H; Chen J; Wang Y; Shi Y
    Immunology; 2020 Aug; 160(4):382-392. PubMed ID: 32306382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti IL-17 in psoriasis.
    Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiovascular comorbidities in psoriasis (Review).
    Branisteanu DE; Nicolescu AC; Branisteanu DC; Branisteanu CI; Dragoi AC; Bogdanici CM; Toader MP; Tucaliuc AL; Dimitriu A; Daogaru D; Pirvulescu RA; Porumb EA
    Exp Ther Med; 2022 Feb; 23(2):152. PubMed ID: 35069833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasis and cardiovascular disorders.
    Ryan C; Menter A
    G Ital Dermatol Venereol; 2012 Apr; 147(2):179-87. PubMed ID: 22481581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purinergic Signaling and Inflammasome Activation in Psoriasis Pathogenesis.
    Ferrari D; Casciano F; Secchiero P; Reali E
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.